Clareo Health | A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genentech, Inc.
Age
60–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Complement Factor I (CFI) profile biomarker-positive result
Women of child bearing potential and men should remain abstinent or use contraceptive methods
You may not be if
History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in study eye
Previous subfoveal focal laser photocoagulation in study eye
Laser photocoagulation in the study eye
Prior treatment with external-beam radiation therapy or transpupillary thermotherapy in study eye
Previous intravitreal drug administration in study eye. A single intraoperative administration of a corticosteroid during cataract surgery at least 3 months prior to screening is permitted
Previous cell-based intraocular treatment in study eye
Intraocular surgery in study eye
Uncontrolled glaucoma and history of glaucoma-filtering surgery in study eye
History of corneal transplant in study eye
GA in either eye due to causes other than AMD
Proliferative diabetic retinopathy in either eye
Active or history of neovascular (wet) AMD in either eye
History of idiopathic or autoimmune-associated uveitis, ocular or intraocular conditions, and infectious or inflammatory ocular disease
Active uveitis and infectious conjunctivitis, keratitis, scleritis or endophthalmitis
Previous systemic treatment with complement inhibitor and with inhibitors/modulators of visual cycle
Uncontrolled blood pressure and atrial fibrillation
Medical conditions associated with clinically significant risk for bleeding-
Predisposition or history of increased risk for infection
Active malignancy within the previous 12 months except for appropriately treated carcinoma in situ of cervix, resolved non-melanoma skin carcinoma, and prostate cancer with a Gleason score of less than or equal to 6, and a stable prostate-specific antigen for greater than or equal to (\>/=) 12 months
History of severe allergic reaction or anaphylactic reaction to a biologic agent or known hypersensitivity to any component of lampalizumab injection
Women of child bearing potential must have a negative serum pregnancy test within 28 days prior to initiation of study treatment
Previous participation in other studies of investigational drugs
